You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Abstract GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.

    SBC: Vova Ida, LLC            Topic: 999

    SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Targeting the sphingolipid pathway for the R&D of new antifungals

    SBC: MICRORID TECHNOLOGIES INC            Topic: NIAID

    ABSTRACT The goal of this project is to discover and develop a new therapeutic smore potent than current antifungals for the treatment of invasive fungal infectionsAmong invasive fungal infectionscryptococcosiscandidiasisand aspergillosis are the most life threateningThe incidence of these infections has risen more thanfold over the lastyearswith a mortality rate ofyearWe recently discovered a fun ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. TeamChip for High-throughput, Predictive Human Metabolism and Toxicology

    SBC: Solidus Biosciences, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute is proposing to address a critical need in chemical safety technology through its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Technology for Non-invasive High-throughput Breath Tracking in Rodents

    SBC: SIGNAL SOLUTIONS LLC            Topic: NHLBI

    ABSTRACTSignal Solutions has developed a novelnoninvasive and automated piezoelectric based sleep detection system for high throughput studies of sleep in miceand has recently expanded to rat studies as wellThe respiratory signal detected by the piezo sensor during sleep can be applied to investigate important health conditions including respiratory depression due to disease or drug useand other s ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Technology for the non-invasive surveilance of post-traumatic compartment syndrome

    SBC: MYOLEX, INC.            Topic: NIAMS

    PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Technology Transfer of the ATLAS and ATHENA Programs

    SBC: Odyssey Science Innovations, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): Over 7.5 million high school students participate in high school sports programs and an additional 2 million students join these athletic teams each year. Adolescent athletes are at risk for using performance enhancing drugs, such as anabolic steroids, unregulated sport supplements, and illicit drugs and alcohol. Unfortunately, few evidence-based substance abus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Testing the feasibility of Rendever with older adults with cognitive impairments and their adult children.

    SBC: RENDEVER, INC.            Topic: NIA

    Alzheimer s disease affects approximatelymillion AmericansNIAand bythis number is expected to more than double tomillionUntil cures for the dementias are discoverednew technologies are imperative that can help reduce the emotional burden of AD ADRD for older adults and their care giversGoal C of NIA s strategic planIn this STTRSmall Business Technology TransferPhase I studywe test the feasibility ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. TFEB Activator for Alzheimer's Disease Therapy

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: NIA

    One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government